Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Published byEdwin Allen Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type."— Presentation transcript:

1 Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type tumors. (B) Forest plot of hazard ratios for progression-free survival time by a priori subgroups in patients with KRAS wild-type tumors. Group A received cetuximab plus FOLFOX-4; Group B received FOLFOX-4 alone. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; ITT, intention-to-treat; LDH, lactate dehydrogenase; OR, odds ratio. From: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol. 2011;22(7): doi: /annonc/mdq632 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

2 Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type tumors. (B) Forest plot of hazard ratios for progression-free survival time by a priori subgroups in patients with KRAS wild-type tumors. Group A received cetuximab plus FOLFOX-4; Group B received FOLFOX-4 alone. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; ITT, intention-to-treat; LDH, lactate dehydrogenase; OR, odds ratio. From: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol. 2011;22(7): doi: /annonc/mdq632 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

3 Figure 2. Kaplan–Meier plots of survival time according to the treatment arm for patients whose tumors were (A) KRAS wild type and (B) KRAS mutant and according to tumor KRAS mutation status for patients receiving (C) cetuximab plus FOLFOX-4 (D) FOLFOX-4 alone. Panel (E) shows survival according to the treatment arm and KRAS tumor mutation status for the four subgroups of patients. CI, confidence interval; FOLFOX, FOLFOX-4; HR, hazard ratio; mt, mutant; OS, overall survival; wt, wild type. From: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol. 2011;22(7): doi: /annonc/mdq632 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

Download ppt "Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type."

Similar presentations

*University Hospital Gasthuisberg, Leuven, Belgium

*University Hospital Gasthuisberg, Leuven, Belgium
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Copyright © 2010 American Medical Association. All rights reserved.

Copyright © 2010 American Medical Association. All rights reserved.
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin  Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin  Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,
Figure 1 (A) Chest computed tomography scans of the patient

Figure 1 (A) Chest computed tomography scans of the patient
Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. (A) Sézary syndrome patient before treatment
Figure 2. Kaplan–Meier survival analysis in patients

Figure 2. Kaplan–Meier survival analysis in patients
Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.
Figure 1. Nonadherence to guidelines for prescribing antiplatelet and anticoagulant therapy in 144 patients with atrial fibrillation who attend a Spanish.

Figure 1. Nonadherence to guidelines for prescribing antiplatelet and anticoagulant therapy in 144 patients with atrial fibrillation who attend a Spanish.
Figure 2. A consort diagram showing the flowchart of the trial

Figure 2. A consort diagram showing the flowchart of the trial
Fig. 1 Selection of patients

Fig. 1 Selection of patients
Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Similar presentations

Ads by Google